Apolipoprotein C-III as a Potential Modulator of the Association Between HDL-Cholesterol and Incident Coronary Heart Disease.
about
Dysfunctional High-Density Lipoprotein: An Innovative Target for Proteomics and LipidomicsNew Era of Lipid-Lowering DrugsThe emerging role of apolipoprotein C-III: beyond effects on triglyceride metabolismWhy Is Apolipoprotein CIII Emerging as a Novel Therapeutic Target to Reduce the Burden of Cardiovascular Disease?Apolipoproteins A-I, B, and C-III and Obesity in Young Adult Cherokee.ApoCIII enrichment in HDL impairs HDL-mediated cholesterol efflux capacityObesity favors apolipoprotein E- and C-III-containing high density lipoprotein subfractions associated with risk of heart diseaseCoronary heart disease risks associated with high levels of HDL cholesterolMonogenic causes of elevated HDL cholesterol and implications for development of new therapeutics.Mapping O-glycosylation of apolipoprotein C-III in MALDI-FT-ICR protein profiles.Racial differences between African-American and white women in insulin resistance and visceral adiposity are associated with differences in apoCIII containing apoAI and apoB lipoproteins.HDL cholesterol, apolipoproteins, and cardiovascular risk in hemodialysis patients.APOL1 G1 genotype modifies the association between HDLC and kidney function in African AmericansTriglycerides on the rise: should we swap seats on the seesaw?Apolipoprotein C-III: a potent modulator of hypertriglyceridemia and cardiovascular disease.The association of HDL-apoCIII with coronary heart disease and the effect of statin treatment on itReduction in lipoprotein-associated apoC-III levels following volanesorsen therapy: phase 2 randomized trial resultsKernel machine testing for risk prediction with stratified case cohort studies.Divergent pathway of lipid profile components for cardiovascular disease and mortality events: Results of over a decade follow-up among Iranian population.Proteomic diversity of high density lipoproteins: our emerging understanding of its importance in lipid transport and beyondAPOC3 induces endothelial dysfunction through TNF-α and JAM-1Molecular sources of residual cardiovascular risk, clinical signals, and innovative solutions: relationship with subclinical disease, undertreatment, and poor adherence: implications of new evidence upon optimizing cardiovascular patient outcomes.Robust risk prediction with biomarkers under two-phase stratified cohort design.The effect of a low-fat, plant-based lifestyle intervention (CHIP) on serum HDL levels and the implications for metabolic syndrome status - a cohort study.Impact of variants in CETP and apo AI genes on serum HDL cholesterol levels in men and women from the Polish populationLooking into the crystal ball-upcoming drugs for dyslipidemia.Novel metabolic biomarkers of cardiovascular disease.Dysfunctional HDL and atherosclerotic cardiovascular disease.New and emerging biomarkers in cardiovascular disease.Key differences between apoC-III regulation and expression in intestine and liver.Identifying new Risk Markers and Potential Targets: The Value of the Proteome.Apolipoprotein C-III Nanodiscs Studied by Site-Specific Tryptophan Fluorescence.Associations of anthropometry and lifestyle factors with HDL subspecies according to apolipoprotein C-III.Diabetes and dyslipidemia: characterizing lipoprotein metabolism.HDL Subspecies Defined by Presence of Apolipoprotein C-III and Incident Coronary Heart Disease in Four Cohorts.ApoCIII as a Cardiovascular Risk Factor and Modulation by the Novel Lipid-Lowering Agent Volanesorsen.Apolipoprotein A-II alters the proteome of human lipoproteins and enhances cholesterol efflux from ABCA1.N-(3-Benzoylphenyl)-1H-Indole-2-Carboxamide decreases triglyceride levels by downregulation of Apoc3 gene expression in acute hyperlipidemic rat model.Using primary murine intestinal enteroids to study dietary TAG absorption, lipoprotein synthesis, and the role of apoC-III in the intestine.Apolipoproteins E and CIII interact to regulate HDL metabolism and coronary heart disease risk.
P2860
Q26774903-F91A1A18-2ACD-4104-9425-F14805F71916Q28072298-B31FA745-1AA5-4536-94B7-1213731DBD0CQ28072835-BB5E7167-634A-4705-9739-1B321F672DB0Q28077776-A3A41945-10C3-42E6-807B-89170F170BFCQ33572201-BE97FD0C-A382-4B50-AF90-350F8007C271Q33725659-69F9BA6B-140D-44E0-A181-FAAD126F3E6DQ34238727-B5A1BD13-90CB-4BA8-8717-A0C58F0DDB9AQ34297247-536C3862-4A5D-4FA0-AA5D-A4D57622E83EQ34441411-83B335E7-7AD0-4465-BA08-D79B7582EA8AQ34555445-8EBA2F88-926B-4164-B482-9C24BE4B4935Q34793857-7B858299-8220-4D63-9C06-E7D9A783E7DBQ35027220-35D984A5-DE95-4651-B820-44CB2B889985Q35646631-BFF0072D-BCA1-410C-9A09-8C8C9D777173Q35753514-6377EEF8-F810-4808-8AA0-1EBE57860009Q35915137-76DF4FF7-9A9C-42C5-8230-F5D22B917F2CQ36144245-D7C54697-D1BB-4321-B209-8B9B882BDBB7Q36731776-0203641B-7F11-4A2F-9AC3-678CEA32D9EEQ36984250-884EFBCA-74F5-4AFB-B9E6-FA78D147AB59Q37035438-D35C209D-CE88-4354-AC6F-746190809DD3Q37162996-A740A691-7E7E-4252-812F-D3A57E1C69F4Q37251472-BF294A74-09F1-428E-9C1F-DCC46B8A017EQ37254899-356729DD-5487-4F23-8A41-B3496B574AABQ37302661-37076AE3-17A8-4B27-AD71-43C8148C44A2Q37361819-E9672973-C272-4C8E-8858-D2A420D791F0Q37412661-0579B516-EC5F-49DE-B8A6-E94B9367B13AQ38235611-769B2EA4-CEBD-4783-8028-D9174B98D711Q38245327-8843DE01-F952-471C-B473-2E294675CA1FQ38577283-945E4F9C-0BDC-4102-80DB-86F3FC284287Q38586900-FDE4B434-B26C-4A01-AB8B-A10569A3FAC5Q38664013-0B4CC976-2D9F-4875-B198-8C3B659DCCEAQ38756916-113A7A59-1198-4957-A953-4E7C2090EA67Q39485969-4F18ECE8-3D18-483D-840F-4A4A2072F559Q40263801-7DD497FD-6306-466C-A208-15444F347190Q41283425-EC8B0527-5397-40B7-8E5E-93F0879F4E8AQ49834367-9551B65B-BE40-4139-90BF-CB8601C11C88Q50075898-8AD6EC86-4D7C-4B25-900A-2B89AECA9E05Q51017649-C3CF28D7-70FB-4869-B1CC-CC0F86A7B3E6Q51113879-84C25504-7640-4073-91F9-423384532C62Q51153525-7B98F218-6852-4526-9AA0-06A9F1285390Q52375183-6985A01C-267E-4FD8-9C69-949D2A659D6F
P2860
Apolipoprotein C-III as a Potential Modulator of the Association Between HDL-Cholesterol and Incident Coronary Heart Disease.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh
2012年學術文章
@zh-hant
name
Apolipoprotein C-III as a Pote ...... cident Coronary Heart Disease.
@ast
Apolipoprotein C-III as a Pote ...... cident Coronary Heart Disease.
@en
type
label
Apolipoprotein C-III as a Pote ...... cident Coronary Heart Disease.
@ast
Apolipoprotein C-III as a Pote ...... cident Coronary Heart Disease.
@en
prefLabel
Apolipoprotein C-III as a Pote ...... cident Coronary Heart Disease.
@ast
Apolipoprotein C-III as a Pote ...... cident Coronary Heart Disease.
@en
P2860
P356
P1476
Apolipoprotein C-III as a Pote ...... cident Coronary Heart Disease.
@en
P2093
Frank M Sacks
Jeremy D Furtado
P2860
P356
10.1161/JAHA.111.000232
P577
2012-04-24T00:00:00Z